| Status | Topic selection |
| Technology type | Medicine |
| Decision | Not selected |
| Reason for decision | Not eligible for Health Technology Evaluation guidance |
| Further information | The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. The NICE-wide prioritisation board met late October 2024 and concluded that the clear rationale to not evaluate this product is due to it being a paediatric licence extension of an existing NHS England commissioning policy for the adult population. NHS England will commission treatments for patients aged less than 18 years where specific commissioning conditions are met as per the Commissioning medicines for children in specialised services policy. Please see eligibility criteria within the prioritisation manual for further information. |
| ID number | 12085 |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic selection